Author(s): Mayer AM, Glaser KB, Cuevas C, Jacobs RS, Kem W, et al.
The global marine pharmaceutical pipeline consists of three Food and Drug Administration (FDA) approved drugs, one EU registered drug, 13 natural products (or derivatives thereof) in different phases of the clinical pipeline and a large number of marine chemicals in the preclinical pipeline. In the United States there are three FDA approved marine-derived drugs, namely cytarabine (Cytosar-U((R)), Depocyt((R))), vidarabine (Vira-A((R))) and ziconotide (Prialt((R))). The current clinical pipeline includes 13 marine-derived compounds that are either in Phase I, Phase II or Phase III clinical trials. Several key Phase III studies are ongoing and there are seven marine-derived compounds now in Phase II trials. The preclinical pipeline continues to supply several hundred novel marine compounds every year and those continue to feed the clinical pipeline with potentially valuable compounds. From a global perspective the marine pharmaceutical pipeline remains very active, and now has sufficient momentum to deliver several additional compounds to the marketplace in the near future; this review provides a current view of the pipeline.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/20363514
Author(s): Haefner B
Author(s): Belarbi el H, Contreras Gómez A, Chisti Y, García Camacho F, Molina Grima E
Author(s): Sipkema D, Franssen MC, Osinga R, Tramper J, Wijffels RH
Author(s): Alcaraz MJ, Payá M
Author(s): Paul VJ
Author(s): Green G
Author(s): Proksch P
Author(s): Taylor MW, Radax R, Steger D, Wagner M
Author(s): Stowe SD, Richards JJ, Tucker AT, Thompson R, Melander C, et al.
Author(s): Thompson JE, Walker RP, Faulkner DJ
Author(s): Beccero MA, Turon X, Uriz MJ
Author(s): Becerro MA, Thacker RW, Turon X, Uriz MJ, Paul VJ
Author(s): Muller WEG
Author(s): Lavrov D
Author(s): By Phil Myers
Author(s): Molinski TF, Dalisay DS, Lievens SL, Saludes JP
Author(s): Simmons TL, Andrianasolo E, McPhail K, Flatt P, Gerwick WH
Author(s): Gordaliza M
Author(s): Hallock YF, Cragg GM
Author(s): Hildebrand M, Waggoner LE, Lim GE, Sharp KH, Ridley CP, et al.
Author(s): Baker DD, Chu M, Oza U, Rajgarhia V
Author(s): Newman DJ, Cragg GM
Author(s): Newman DJ, Cragg GM
Author(s): Sagar S, Kaur M, Minneman KP
Author(s): Villa FA, Gerwick L
Author(s): Frota MJ, Silva RB, Mothes B, Henriques AT, Moreira JC
Author(s): Blunt JW, Copp BR, Keyzers RA, Munro MH, Prinsep MR
Author(s): Shaaban M, Abd-Alla HI, Hassan AZ, Aly HF, Ghani MA
Author(s): Longeon A, Copp BR, Quévrain E, Roué M, Kientz B, et al.
Author(s): Utkina NK
Author(s): Li Z
Author(s): Sugiyama Y, Ito Y, Suzuki M, Hirota A
Author(s): Kim SK, Dewapriya P
Author(s): Berrué F, McCulloch MW, Boland P, Hart S, Harper MK, et al.
Author(s): Abraham I, El Sayed K, Chen ZS, Guo H
Author(s): Crews P, Gewick WH, Schmitz FJ, France D, Bair KW, et al.
Author(s): Wang YQ, Miao ZH
Author(s): Bergmann W, Feeney RJ
Author(s): Proksch P, Edrada RA, Ebel R
Author(s): Schwartsmann G
Author(s): Feldman EJ, Lancet JE, Kolitz JE, Ritchie EK, Roboz GJ, et al.
Author(s): Essack M, Bajic VB, Archer JA
Author(s): Sipkema D, Osinga R, Schatton W, Mendola D, Tramper J, et al.
Author(s): Newman DJ, Cragg GM
Author(s): Halim H, Chunhacha P, Suwanborirux K, Chanvorachote P
Author(s): Guzii AG, Makarieva TN, Denisenko VA, Dmitrenok PS, Kuzmich AS, et al.
Author(s): Kondracki ML, Guyot M
Author(s): Kong D, Yamori T, Kobayashi M, Duan H
Author(s): Bai R, Cichacz ZA, Herald CL, Pettit GR, Hamel E
Author(s): Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, et al.
Author(s): Valeriote FA, Tenney K, Media J, Pietraszkiewicz H, Edelstein M, et al.
Author(s): Rabelo L, Monteiro N, Serquiz R, Santos P, Oliveira R, et al.
Author(s): Schumacher M, Cerella C, Eifes S, Chateauvieux S, Morceau F, et al.
Author(s): Shin BA, Kim YR, Lee IS, Sung CK, Hong J, et al.
Author(s): Zhao Q, Mansoor TA, Hong J, Lee CO, Im KS, et al.
Author(s): Gunasekera SP, Cranick S, Longley RE
